Interpace Biosciences
CMS Contractor Novitas Rescinds Noncoverage Decision for Cancer Genetic Tests
The original decision rescinded coverage for tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Abbott, Clinical Genomics, and the University of Pittsburgh Medical Center.
CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests
Novitas reviewed, analyzed, and published literature for a variety of genetic oncology tests and highlighted several that it claims are not medically reasonable or necessary.
Interpace Biosciences to Stop Offering Pancreatic Cancer Test After Losing CMS Reimbursement
Novitas said in its coverage determination that the test has not demonstrated incremental clinical value in the prognosis of pancreatic cysts and associated cancer.
Earnings Roundup: Accelerate Diagnostics, Exagen, Lucira Health, More
Accelerate, Exagen, Lucira, Lucid Diagnostics, and Interpace Biosciences reported their quarterly financial results this week.
Interpace Biosciences Posts 6 Percent Revenue Increase in Q1
The company said that it experienced improved reimbursement rates and clinical services volume for its thyroid cancer tests compared to Q1 of last year.